Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!

NetraMark Holdings: 50% upside potential

NetraMark shares currently offer an attractive entry opportunity. After a failed breakout attempt from its sideways trend, shares of the Canadian AI specialist, which are also traded on Tradegate, are now trading at CAD 1.48. The price target set by analysts at Zacks Small-Cap Research is CAD 2.25, meaning an upside potential of around 50%. Pharma and biotech companies can save billions in drug development using NetraMark's proprietary AI platform, NetraAI. The software improves efficiency, precision, and regulatory compliance of clinical trials through AI-driven analytics. For context: McKinsey management consultants estimate that the pharmaceutical industry spent around USD 247 billion on research and development in 2022. The savings potential is therefore enormous.

General AI systems such as ChatGPT and DeepSeek appear to reach their limits when it comes to these highly specific tasks. NetraAI outperformed both in a comparative test. The results published in July showed that NetraAI outperforms its competitors in the analysis of real-world, highly complex clinical trial data. NetraMark AI was the only one to identify reliable, clinically actionable insights in three independent studies on schizophrenia, depression, and pancreatic cancer. The accuracy of its predictions of treatment outcome exceeded 90% in some cases. ChatGPT and DeepSeek were only able to produce unusable clusters or generic texts.

NetraAI is already being used in practice. Among other things, a global agreement was signed with CRO Worldwide Clinical Trials in April 2025. The contract research organization conducts clinical trials for pharmaceutical and biotech companies worldwide and offers customers the NetraAI platform to optimize their studies. In addition, several pharmaceutical and biotech companies are already relying on NetraMark's AI. These include Asklepion Pharmaceuticals, for example. They are using the NetraAI platform in a pivotal pediatric Phase III trial on the efficacy of intravenous L-citrulline (CIT-003-01) for the prevention of acute lung injury in children.

Puma: Merger with Adidas a crazy idea?

Are Puma and Adidas merging? This sounds both spectacular and crazy at the same time. After all, the two sporting goods manufacturers are archrivals. The tensions date back to the split between the Dassler brothers in Herzogenaurach in 1948. To this day, they regularly poach each other's top managers. Yet, it was precisely this idea of a merger that Roy Adams recently floated in an interview with Handelsblatt. From the perspective of the manager of US investor Metronuclear, Adidas should take advantage of the difficult situation of its smaller competitor and swallow Puma. Adams explained that Puma was in a "state of emergency" - its share price has fallen sharply this year, operating performance is weak, and if management fails to take adequate measures, a merger with Adidas would be the best option. This speculation caused a media stir, but only led to a slight rise in the Puma share price. The muted reaction suggests that investors are not convinced the idea will materialize.

There were plenty of comments on the proposal. Opinions differ. Some see potential, while others warn of practical and strategic hurdles. Analysts at DZ Bank, for example, believe that the idea of a merger has "a certain charm at first glance" - precisely because of the historical connection between the two companies. But on closer inspection, there is little concrete benefit for Adidas. Instead, there is a risk of cannibalization, as the brands are positioned very similarly. The integration of such a large acquisition also carries significant risks.

JPMorgan warns of the difficulty of adequately managing a turnaround program and the merger at the same time. The effort and complexity would be too great for Adidas. There is a lot of overlap between the brands. In addition, the costs of standardizing brands, logistics, and distribution are difficult to estimate.

Overall, many experts agree that the idea is exciting, but so far, there are no signs that Adidas is pursuing a concrete merger plan. Uncertainty about costs, brand integration, and shareholder interests remains high.

Evotec: Another insider purchase

Are we seeing a tentative attempt at recovery in Evotec shares with the rise above the EUR 6 mark? In any case, it is too early to speak of a trend reversal. In recent weeks, the German biotech company's shares have been characterized by a mixture of negative impulses and short-term attempts at recovery. The last major sell-off was triggered in July by the reduction of the revenue forecast of EUR 760 million to EUR 800 million (previously: EUR 840 million to EUR 880 million). This was followed by a decline in the share price from EUR 7.46 to EUR 5.70. To put this into context: In October 2021, the share price of the former German biotech hope stood at around EUR 45.

At least top management appears to see the current level as an opportunity to buy. On August 27, 2025, CEO Christian Wojczewski purchased shares worth just under EUR 300,000. The price was EUR 5.92 per share. A few days ago, fellow board member Paul Hitchin also made a move. He bought Evotec shares worth around EUR 74,000 at a price of EUR 5.91.

Insider purchases are generally seen as a sign that executives have confidence in the Company's medium-term prospects. At Evotec, the share price has not yet recovered sustainably. Perhaps management will be able to convince investors in the coming week. On September 22, Evotec will participate in the virtual CMO conference and the following day in the German Corporate Conference hosted by Berenberg and Goldman Sachs in Munich.

Based on its operational performance, there is a good chance that NetraMark shares will reach the analysts' price target. This would represent a 50% upside potential. However, the sideways trend must first be broken. Economically, the idea of a merger between Puma and Adidas is justified, especially if Puma is unable to overcome its crisis on its own. In practice, however, the integration risks would be enormous. Insider purchases at Evotec are certainly a positive signal, but more is needed for a sustained upward trend.